Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Panel Approves 18th Edition of Japanese Pharmacopoeia; 33 New Products Added
A health ministry panel on October 5 approved a proposed 18th edition of the Japanese Pharmacopoeia. The new edition will include new monographs on 33 drugs including celecoxib (brand name: Celecox). The Pharmaceutical Affairs Council will discuss in December the…
To read the full story
Related Article
- MHLW Panel OKs 19th Edition of Japanese Pharmacopoeia; 27 New Products Added
October 14, 2025
- 33 New Products Including Celecoxib Added to 18th Edition of Japanese Pharmacopoeia
June 8, 2021
- Basic Policy on JP 18th Edition Calls for Expansion of Sections Related to Biopharmaceuticals: MHLW
October 21, 2016
- Basic Policies for JP 18th Edition Now Up for Public Comments
August 23, 2016
- MHLW Panel OKs Basic Policies for Next JP Edition, Due Out 2021
July 21, 2016
- 76 Products Join Japanese Pharmacopoeia: MHLW
March 10, 2016
- Panel OKs Revised Japanese Pharmacopoeia, 76 Products Newly Included
September 18, 2015
REGULATORY
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…